Valuation: Harvard Bioscience, Inc.

Market Cap 31.73M 27.22M 25.42M 23.32M 43.85M 3.03B 44.57M 300M 117M 1.52B 119M 117M 5.03B P/E 2026 *
-3.58x
P/E 2027 * -15x
Enterprise Value 31.73M 27.22M 25.42M 23.32M 43.85M 3.03B 44.57M 300M 117M 1.52B 119M 117M 5.03B EV / Sales 2026 *
0.35x
EV / Sales 2027 * 0.34x
Free-Float
90.61%
Yield 2026 *
-
Yield 2027 * -
1 day+0.86%
1 week+14.26%
Current month+15.57%
1 month+15.38%
3 months+40.72%
6 months+20.29%
Current year+5.41%
1 week 6.08
Extreme 6.0792
7.23
1 month 5.91
Extreme 5.9101
7.23
Current year 4
Extreme 4
7.5
1 year 3.76
Extreme 3.755
9.4
3 years 2.81
Extreme 2.813
55.6
5 years 2.81
Extreme 2.813
84.8
10 years 2.81
Extreme 2.813
87.5
Manager TitleAgeSince
Chief Executive Officer 55 28/07/2025
Director of Finance/CFO 63 12/05/2025
Chief Tech/Sci/R&D Officer - 01/04/2019
Director TitleAgeSince
Director/Board Member 52 24/10/2017
Director/Board Member 55 02/06/2025
Director/Board Member 52 16/07/2025
Date Insider Type Main position Quantity % Market Cap.
20/3/26 Free

Chief Financial Officer

30,000 0.0671%
17/12/25 Free

Director

110,000 0.2467%
17/12/25 Other

Director

750,000 1.6824%
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%+14.26%+44.76%-83.05% 31.73M
+4.46%+2.09%+23.55%+15.67% 218B
+6.14%+2.82%-0.29%-15.42% 140B
+2.39%-0.22%-16.45%+39.66% 138B
+3.90%+1.79%-49.55%+3.81% 73.14B
+1.62%-0.80%+16.95%+20.94% 52.44B
+1.32%+2.43%-16.15%-12.09% 50.85B
+4.32%+4.86%+29.42%+30.78% 41.92B
+3.76%+0.47%+40.44%+56.50% 39.42B
+2.57%+3.24%+0.88%+8.19% 32.81B
Average +3.12%-0.40%+7.36%+6.50% 78.69B
Weighted average by Cap. +3.82%-2.40%+2.69%+14.33%

Financials

2026 *2027 *
Net sales 89.8M 77.03M 71.93M 65.99M 124M 8.58B 126M 849M 332M 4.3B 337M 330M 14.23B 94.55M 81.1M 75.73M 69.48M 131M 9.04B 133M 894M 350M 4.53B 355M 347M 14.99B
Net income -8.9M -7.63M -7.13M -6.54M -12.3M -851M -12.5M -84.12M -32.94M -427M -33.42M -32.69M -1.41B -2.2M -1.89M -1.76M -1.62M -3.04M -210M -3.09M -20.79M -8.14M -105M -8.26M -8.08M -349M
Net Debt - -
Logo Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Employees
328
Date Price Change Volume
20/08/26 USD 7.050 +1.15% 7,441
18/08/26 USD 6.970 +7.23% 51,066
17/08/26 USD 6.500 -2.33% 13,283
14/08/26 USD 6.655 -0.22% 15,416
13/08/26 USD 6.670 +8.10% 51,926
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.970USD
Average target price
7.500USD
Spread / Average Target
+7.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HBIO Stock